This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) | MicrobiomeTrials
← Back to trials NCT06436742
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-09-24Est. Completion: 2027-08-24
Enrollment target: 15 participantsLocations UC Davis Medical Center, Sacramento, California, United States Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States Ottawa Hospital Research Institute - Civic Campus, Ottawa, Canada CHU - Hospital de la Timone, Marseille, France Group Hospitalier Pitie-Salpetriere, Paris, France Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur), Valencia, Spain Clinical Trials Centre - South Eastern Health and Social Care Trust - The Ulster Hospital, Belfast, United Kingdom John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom Other microbiome trials you might be interested in Solid Tumors Hematologic Malignancies
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants fr…
Tucson, United States Est. completion Aug 4, 2043
Congenital Myasthenic Syndrome
Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participant…
Sacramento, United States Est. completion Jun 2027